Like I said, he expanded talk about the clinical progress on the drugs we have, but investors want action already! Enough clinical graphs. Action!
Stoney learned nothing from DYAX pps success. My guess is he's not looking for a buyout, so pps doesn't matter.
To an extent that may be true for Biocryst. We fell badly due to the malaise since the dawn of 2016. January blues.
But, Like the CEO of DeCode Genetics, our CEO is reporting good science, but he's been doing that for quite a while. The street is looking for some numbers already. It's high time. We were at 10 or 11 for a while with no real catalyst to go up or down, except for some teasers. Come January, the excuse to go negative appeared, and now we are stuck at 7. DYAX took what little they had and sold it. They are in the upper 20's. They barely got touched this year. Sorry guys, but our CEO is straightforward, honest, and intelligent; but investors are short sighted and dumb.
February's results better be excellent, or this stock is toast!
"Baxalta shareholders probably got a decent deal" Somebody, please explain how a deal supposedly worth 45 a share causes the pps to fall to 39.
So this tells me that any of the discussion by management about stockpiling has been very premature, read misleading expectations. Stockpiling changes and additions are probably a year off at least. Don't count it in the equation.
NBI over 100 today. BCRX starts up 40 cents, then fell to even. This is the first time in weeks that BRCX has not gone up or down with the biotech indices.
Lysander - " As map says, the revenue news can come when least expected, without fanfare."
Sorry guys, but I was just in a warm shower and a sudden chill hit me; Biocryst may not get that revenue they so long have coveted. The difference between self funding (e.g.,GILD) and govt funding projects. And it has nothing to do with GOVT. It has to do with the simultaneous funding of lots of projects, and may the best win. NIH owes Biocryst nothing. GILD went to Britain to test using their own money, after first submitting some failed HCV drugs for Ebola testing at NIH. After phase 1 success, with their own money, they can do whatever they want. That's the price Biocryst, and shareholders) pay.
Listen up, in spite of that the pps has been pretty good.
Too much information. No one can ever accuse Jon of pumping! He is a straight shooter. But, maybe he shouldn't even mention anymore what the plan is if they don't get the 2 year extension on animal carcinogenicity studies.
thx for the input. my problem is basically management lack of clarity. surely, more can be said than "waiting on the govt." how long do they think they can get a pass on that?
I am not sure that Biocryst is on the up and up as far as BCX4430.
Phase 1 study by Quotient in Nottingham England (see Clinicaltrials entry - updated Dec. 2) was stated to run from Dec, 2014 thru July, 2015 on 88 patients. They present as a very efficient company that runs phase 1 trials. Up till Oct, 2015 Biocryst always blames 4430 delay on the govt. Excuse me,. but clinicaltrials says Biocryst is responsible for the phase 1 study. Credibility disappears rapidly on the street.
Stonehouse saying "its the govt" is misleading. Read the article (www.acs.cen.org) and you will see that Gilead has pulled out all the stops on this and has produced a drug that works 100% in Ebola on monkeys, and may just have cured the Scottish nurse. It seems that USAMRIID prefers larger companies, especially ones with proven antivirals. It's just the way it is. Keep in mind, the ultimate goal is to get a pan-anti-RNA-virus drug, and I believe Biocryst has a shot. Just don't hold your breath waiting.
Pardon folks, but this seems to be the only way I can get a post to stick this morning
Treat Biocryst development of BCX4430 as a long-shot extra. It is a good thing that USAMRIID is funding the project - it means there is more than a passing interest. Don't count on it for the future of Biocryst.
Read "Hard Lessons in Ebola Research" now appearing in the Nov. 16 issue of Chemical and Engineering News. Sina Bavari, chief scientific officer of USAMRIID, talks about Gilead's GS-5734: "If we wouldn't have found the Gilead compound, I would probably still have nightmares like I did a year ago." Scottish nurse Cafferkey was given GS-5734. She's OK now. BCX4430 is only mentioned in a "Sparse Pipeline" table.
Again, and I quote the article - " The only new addition to the field is Gilead's GS-5734, a nucleoside inhibitor that has done a great job of helping even the sickest of infected monkeys." The text of the article mentions Tekmira, ZMapp, Fujifilm, but not Biocryst.